Kornimate/medical-research-clean huggingface dataset:
a study of abemaciclib (ly2835219) in participants with previously treated breast cancer that has spread

Conditions: Metastatic Breast Cancer

Summary: the main purpose of this study is to evaluate whether the study drug known as abemaciclib is effective in treating participants with breast cancer who have already tried other drug treatments.


Eligibility criteria:
inclusion criteria. * have a diagnosis of hormone receptor positive (hr+), human epidermal growth factor receptor 2 negative (her2-) breast cancer. * recurrent, locally advanced, unresectable or metastatic breast cancer with disease progression following anti-estrogen therapy. * prior treatment with at least 2 chemotherapy regimens: * at least 1 of these regimens must have been administered in the metastatic setting. * at least 1 of these regimens must have contained a taxane. * no more than 2 prior chemotherapy regimens in the metastatic setting. * have a performance status (ps) of 0 to 1 on the eastern cooperative oncology group scale. * have discontinued all previous therapies for cancer. * have the presence of measureable disease as defined by response evaluation criteria in solid tumors version 1.1. exclusion criteria: * have either a history of central nervous system (cns) metastasis or evidence of cns metastasis on the magnetic resonance image of brain obtained at baseline. * received prior therapy with another cyclin-dependent kinases 4 and 6 (cdk4/6) inhibitor. * have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug. * have had major surgery within 14 days of the initial dose of study drug. * have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).

Keywords: endocrine therapy, taxane, monarch 1
hypothermia in cesarean sectio patients in regional anaesthesia

Conditions: Cesarean Section

Summary: to study the core temperature perioperatively in patients due for elective cesarean sectio in spinal anaesthesia. core temperature will be registered by a zero-flux (spoton. 3m) probe on the forehead, starting in the holding area and continued until normotemperature post-operatively.


Eligibility criteria:
inclusion criteria: * elective patients * planned spinal anaesthesia exclusion criteria: * conversion of procedure to general anaesthesia * allergy to temperature probe (adhesive)
assessment of the prevalence of sarcopenia in early palliative cancer patients

Conditions: Metastatic Cancer

Summary: cancer is one of the leading causes of death in the world after cardiovascular disease (8.7 million deaths in 2015 for 17.5 million cases) 1. despite a great deal of progress in disease detection and treatment, the incidence of cancer is steadily increasing (+ 33% in 2015) and particularly in certain locations (pancreas, lungs, brain and stomach), including risk factors are not always identified. advanced stage cancer (= metastatic) is most often incurable with the exception of germ cell tumors. palliative care is then most often offered. palliative care favors the patient's quality of life as a whole (medical, physical, psychological and social). the symptoms most often reported by patients are: pain, fatigue, decreased appetite, nausea, and are directly related to phenomena such as cachexia, loss of autonomy and deterioration of psychological state, resulting in decreased overall survival. chemotherapies and targeted therapies (immunotherapy, hormonal therapy, participation in a clinical trial) can provide a benefit in quality of life and survival only in the early phase (little benefit in the terminal phase). other prognostic factors can impact the quality of life and overall survival in these situations: sarcopenia and disorders of nutritional status (obesity, undernutrition). the study of sarcopenia by ct scan of patients in a palliative situation is still too scarce. sarcopenia is an often underestimated event and is associated with older age, co-morbidities, increased infectious complications, and early mortality. the study of the prevalence of sarcopenia by ct scan would confirm its prognostic impact in a palliative situation.


Eligibility criteria:
inclusion criteria: * age\> 18 years old, * patient with solid cancer diagnosed with metastatic disease, * having had a biological assessment and a ct scan in the month preceding the medical consultation, * and whose prognosis is considered palliative exclusion criteria: * age \<18 years old, * adults under guardianship measure, * pregnancy or breastfeeding in progress, * malignant hemopathies, * metastatic germ cell tumors, * non-metastatic disease
target intracranial aneurysm coiling registry

Conditions: Intracranial Aneurysms

Summary: the purpose of this prospective registry is to collect real world, post-marketing data on the use of stryker target® 360,target® 2d, and 2nd generation target® nano coils for the embolization of ruptured or unruptured intracranial saccular aneurysms. up to 300 patients (150 in the target 360°/helical arm and 150 in the new nano arm) presenting with intracranial aneurysms suitable for coil embolization will be enrolled at up to 20 sites. a post hoc analysis comparing target® 360° and target® 2d coil technical and clinical endpoints will be performed.


Eligibility criteria:
inclusion criteria: 1. patient is 18 years or older. 2. patient has a documented, previously untreated, saccular intracranial aneurysm, unruptured or ruptured, suitable for embolization with coils. 3. (new nano arm only) target aneurysm is ≤7mm. 4. patient has a hunt and hess score of 3 or less. 5. patient has a premorbid mrs of 3 or less. 6. patient or patient's legally authorized representative has provided written informed consent. 7. patient is willing to and can comply with study follow-up requirements. exclusion criteria: 1. patient is \< 18 years old. 2. dissecting aneurysm. 3. patients with intracranial aneurysms (other than the target aneurysm) that will require treatment during the study period (enrollment through follow-up). 4. patients in whom the target aneurysm will be treated with coils other than stryker target® 360°, target® helical coils, and 2nd generation target® nano coils. 5. (new nano arm only) patients in whom the target aneurysm was treated with a total coil length comprised of \<25% stryker target® 2nd generation nano coils. 6. target aneurysm is fusiform. 7. patients in which the target aneurysm cannot be coiled in one procedure (i.e. staged procedure)

Keywords: intracranial aneurysm cerebral aneurysm packing density target coils aneurysm embolization
differentiation of progression from treatment effects in high-grade gliomas: a clinical trial with multimodality mr imaging

Conditions: Glioma

Summary: to evaluate the efficacy of multi-modality magnetic resonance quantitative parameters in evaluating the treatment effects of high-grade gliomas, and to provide new biomarkers for the establishment of new diagnostic criteria for the identification of true and pseudoprogression of high-grade gliomas.


Eligibility criteria:
inclusion criteria: 1. patients with high-grade gliomas confirmed by pathology and have not been treated with concurrent chemoradiotherapy; 2. written informed consent is obtained. exclusion criteria: 1. patients not suitable for enhanced mri scanning of patients; 2. patients who have not finished follow-up concurrent chemoradiotherapy or mr scanning.
3dknee™ system vs. the mjs knee system

Conditions: Rheumatoid Arthritis; Traumatic Arthritis; Joint Disease Secondary to Osteoarthritis

Summary: the purpose of this study is to compare the survivorship and efficacy of the encore 3dknee™ system with that of the encore mjs™ knee system in a group of 600 patients for whom data collection is already under way.

the purpose of this study is to compare the survivorship and efficacy of the encore 3dknee™ system with that of the encore mjs™ knee system in a group of 600 patients for whom data collection is already under way. approximately 300 patients have already received the mjs™ knee system and data, as described below, has been collected for these patients over a period of two years. a second group of 300 patients will receive the encore 3dknee™ system over the next two years, and equivalent data will be collected for these individuals. a portion of the data has been collected over the past year, and now we would like to obtain permission from the patients to analyze these data as well as collect an additional year of data.

Eligibility criteria:
inclusion criteria: * this must be a primary knee replacement on this knee. * patient is over 18 years of age or older * patients must have one of the following * rheumatoid or traumatic arthritis or * joint disease secondary to osteoarthritis * patient is likely to be available for evaluation for the duration of the study * able and willing to sign the informed consent and follow study procedures * patient is not pregnant exclusion criteria: * is younger than 18 years of age * if there has been a total knee replacement on this knee in the past (no revisions allowed in study) * overt infection * alcoholism or other addictions * muscular, neurological or vascular deficiencies which compromise the affected extremity * obesity * marked bone loss * materials sensitivity * prisoner * mental conditions that may interfere with the patient's ability to give an informed consent or willingness to fulfill the study requirements * patient is pregnant
modified reporting of positive urine cultures collected from long term care

Conditions: Urinary Tract Infections; Asymptomatic Bacteriuria

Summary: asymptomatic bacteriuria (ab) is a condition in which bacteria are detected in urine culture without urinary symptoms. the inappropriate use of antibiotic treatment for ab selects bacterial flora to express resistance mutations. reducing inappropriate antibiotic use for ab is difficult, since the microbiology laboratory cannot distinguish patients with ab. the investigators study will use a restricted laboratory report requesting the physician to call the laboratory for culture results. the restricted report may reduce the rate of inappropriate treatment of ab.

positive urine cultures during the study period will be randomized to restricted microbiology laboratory reporting or standard microbiology laboratory reporting. physician or patient consent will not be collected. patient records will be assessed by the investigator to determine if patients have ab or urinary tract infection. physician antibiotic treatment decision in both groups will be collected.

Eligibility criteria:
inclusion criteria: 1. consecutive positive urine cultures collected from patients admitted to long term care facilities will be included. all methods of urine collection will be included (midstream, in-and-out catheterization, indwelling catheter). exclusion criteria: 1. positive urine cultures not collected from long term care facility patients 2. pregnancy 3. antibiotic treatment at the time of collection 4. patients known to have blood neutrophils \<1.0 within 7 days of urine collection

Keywords: long term care urine culture
comparison of visual outcomes with mini-monovision between a monofocal and an adjustable intraocular lens

Conditions: Cataract

Summary: this study is a single center, multi-surgeon, prospective, randomized, comparative study of binocular corrected distance visual acuity (cdva) after successful bilateral cataract surgery. subjects will be assessed pre-operatively, operatively and at up to 6 postoperative visits. clinical evaluations will include administration of patient reported spectacle usage questionnaire (prsiq), as well as measurement of monocular and binocular visual acuities at distance, intermediate, and near, defocus curve, manifest refraction, measurement of higher order aberrations.


Eligibility criteria:
inclusion criteria: subjects are eligible for the study if they meet the following criteria: note: ocular criteria must be met in both eyes. * adult patients undergoing age-related cataract surgery with expected best- corrected visual outcomes of 20/25 or better * regular corneal astigmatism of 0.75d-2.50d * dilated pupil diameter of 7mm or greater exclusion criteria: if any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study. * moderate-severe corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases that is expected to cause future vision loss, glaucoma, severe dry eye disease, history of uveitis, ocular herpes simplex virus, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation. * history of corneal refractive and intraocular surgery. * patients taking systemic medication that may increase sensitivity to uv light or that may cause toxicity to the retina. the principal investigator reserves the right to declare a patient ineligible or non- evaluable based on medical evidence that indicates they are unsuitable for the trial. pregnancy has a known effect on the stability of refractions and visual acuity. as such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.
sex differences in oral bacteria

Conditions: Cardiovascular Disease

Summary: females have a lower incidence of hypertensive and cardiovascular disorders that may relate to differences in nitrogen oxides in the blood and saliva. some nitrogen oxides are recycled with the help of oral bacteria to nitric oxide which is protective against vascular disorders. this study will test the hypothesis that females have different numbers and species of these nitrogen-oxide reducing bacteria.


Eligibility criteria:
inclusion criteria: * healthy subjects aged 18-45 who have volunteered themselves and are willing to sign the consent form exclusion criteria: 1. healthy subjects unwilling to consent 2. history of hypertension, diabetes or hypertensive on bp measurement 3. pregnant, or any possibility that a subject may be pregnant unless in the latter case a pregnancy test is performed with a negative result 4. history of any serious illnesses, including recent infections or trauma 5. subjects taking systemic medication (other than the oral contraceptive pill) 6. subjects with self-reported use of mouthwash or tongue scrapes 7. subjects with recent or current antibiotic use (within 3 months) 8. subjects with a history, or recent treatment of (within last 3 months) of any oral condition (excluding caries), including gingivitis, periodontitis and halitosis
effect of focused ultrasound on abdominal and intrahepatic fat in patients with non-alcoholic fatty liver disease

Conditions: Fatty Liver

Summary: in recent years, a number of modalities have become available for the noninvasive reduction of adipose tissue. one of those is high intensity focused ultra sound (hifu). the study aimed to discover the effect of focused ultrasound on localized abdominal fat size in fatty liver patients. methods: in total, 40 participants with a body mass index (bmi) 30-40 kg/m2, whose age ranged between 30 and 45 years, mild to moderate fatty liver (liver to spleen ratio \< 1), and with waist-hip ratio (whr) greater than 0.8 for females and greater than 0.95 for males were included. the participants were randomly assigned to two groups, one group received focused ultrasound, diet, and exercises (the study group) and the other group received exercises, and diet only (the control group), respectively. measures were abdominal subcutaneous fat volume, abdominal visceral fat volume, and liver to spleen ratio (l/s ratio) were measured at the beginning of the study and 3 months later.


Eligibility criteria:
inclusion criteria: participants with a body mass index (bmi) 30-40 kg/m2, whose age ranged between 30 and 45 years, mild to moderate fatty liver (liver to spleen ratio \< 1), and with waist hip ratio (whr) greater than 0.8 for females and greater than 0.95 for males were included exclusion criteria: abdominal hernias, severe diabetes or autoimmune diseases; patients with osteoporosis, phlebitis and thrombophlebitis; patients with metallic sections, articular prosthesis, intrauterine devices or a pacemaker; pregnant women; patients with a reduced nervous sensibility or with neurological pathologies; patients with obliterating arteriopathies and patients with important inflammatory processes or neoplastic diseases
effects of marijuana used on lung function in persons with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the main hypothesis is that persons that smoke or smoked tobacco and marihuana have worsen lung function as compared with persons that only smoke or smoked tobacco.

we will follow persons with already diagnosed copd (chronic bronchitis and/or emphysema). obtain their smoking history: tobacco and marihuana and review their pulmonary function study results. then we are planning to compare both groups.

Eligibility criteria:
inclusion criteria: * copd patients former or current tobacco smokers * copd patients former or current tobacco and marihuana smokers exclusion criteria: * history of copd without pulmonary function testing * refusal to provide smoking or marihuana used history

Keywords: copd pulmonary function tobacco and marihuana smoking
imaging biomarkers in spastic paraplegia type 5

Conditions: Spastic Paraplegia Type 5A, Recessive

Summary: this is a research study aiming to identify imaging biomarkers in patients diagnosed with spastic paraplegia type 5 (spg5)

"the aim of this study is to identify robust and reliable imaging biomarkers of disease by using novel macrostructural (volumetry), microstructural (fiber tractography) and spectroscopy (metabolites) methods to calculate spg5 patients biometrics using a commercially available medical software brain quant (licence bt-bq-001-start, market caih, ce12331), an approach with a larger effect size than conventional methods." this study will recruit 10 spg5 patients. each participant will be invited to a one-day session during which a clinical examination will performed and an edss score will be assigned, followed by a brain and a spine mri/mrs examination. clinical implications: this study will define biomarkers that can be quantified in spg5 patients and that could be used as read-outs to assay therapeutic effects in clinical trials focused on spg5 patients

Eligibility criteria:
inclusion criteria * at least 18 years of age * signature of the informed consent * covered by social security * spg5 patients identified with two mutations in the cyp7b1 gene exclusion criteria * contra-indications to mri (claustrophobia, metallic or material implants) * additional psychiatric or neurological conditions / additional major comorbidities * history of severe head injury * participation in another trial (except observational trial) * pregnancy and breastfeeding * inability to understand information about the protocol * persons under ame * persons deprived of their liberty by judicial or administrative decision * adult subject under legal protection or unable to consent * unwillingness to be informed in case of abnormal mri

Keywords: spastic paraplegia metabolism magnetic resonance imaging expanded disability status scale (edss) brain spine
pancreatic disease cohort of toulouse

Conditions: Pancreatic Diseases

Summary: this study is a prospective cohort dedicated to pancreatic diseases excluding cancer. the aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. during this study the investigators collect data and biological samples to support research project.

this collection focuses on pathology of the pancreas requiring specific investigations or management for diagnosis or treatment. pancreatic pathologies can be classified as malignant, potentially malignant or benign tumors. these can be solid or cystic. there is an inflammatory attack on the pancreas, generating acute pancreatitis in the acute period, if the inflammatory manifestations persist, chronic pancreatitis will develop. some lesions may be at risk of malignancy during their evolution, it is therefore necessary to improve the performance of monitoring and diagnostic tools in order to adapt the management of patients.

Eligibility criteria:
inclusion criteria: * patients with inflammatory or cystic exocrine pancreatic pathology * patient able to read and understand the information leaflet * patients who have agreed to participate in the study and have signed the free and informed consent * patients affiliated to a social security system (including ame) exclusion criteria: * patient with pancreatic cancer pathology * patients with active cancer, whatever the origin * pregnant or breastfeeding patients * patients under legal protection, guardianship or trusteeship

Keywords: pancreatic cyst acute pancreatitis chronic pancreatitis intra pancreatic mucinous neoplasia diagnosis
to find effectiveness of stretching versus soft tissue mobilization in coccydynia in postpartum females

Conditions: Coccidioidomycosis

Summary: this research is to determine the effectiveness of stretching versus soft tissue mobilization in coccydynia patients.the main purpose of the study is the the development of evidence based therapeutic protocols for postpartum coccydynia patients to improve functional impairment, range of motion, and reduction of pain.

the study design is randomized controlled trial.the interventions were carried out twice a week for three weeks with each session lasting approximately 20 min.group a contains 34 patients and received stm focusing on mobilizing soft tissue to enhance circulation reduce scar tissue and improve functional flexibility.group b received both stm and stretching twice a week for three weeks with each session lasting approximately 20 min.during entire treatment the therapist kept close eye on patient discomfort.the significance of the study lies in it's potential to enhance more effective non invasive treatment to alleviate symptoms

Eligibility criteria:
inclusion criteria: * diagnosed by orthopedic surgeon with sign and symptoms of coccydynia and radiograph x ray for confirmation.: postpartum females after 2 to 3 months after delivery * office working females * aged 20 to 35 years * females with c section exclusion criteria: * females with vaginal delivery * experience severe post operative pain * active pelvic or abdominal infections * ovarian cyst, fibroids,or obstructive endometrial polyps * neurological conditions
the long-term neurodevelopmental outcome after intraventricular hemorrhage (ivh)-grades i-ii in preterm infants at ages 1-7 years

Conditions: Premature Infants

Summary: it is well-known that preterm delivery can be accompanied by complications. one of these complications is intraventricular hemorrhage (ivh). there are four degrees of ivh, according to severity. it is known that ivh grades 3-4 can cause severe neurodevelopmental outcomes, including cerebral palsy (cp), hemiplegia, lower motor and cognitive skills and social difficulties. it is not known whether ivh grades i-ii have any of these effects and the aim of this study is to determine whether they do have any neurodevelopmental outcomes.


Eligibility criteria:
inclusion criteria: * all preterm infants born at 35 weeks or less * underwent at least 1 brain ultrasound * diagnosed with ivh grades 1-2 * had no other severe illness in nicu * had neurodevelopmental follow-up exclusion criteria: * all others